Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“ALLHAT”-Type Cardio Safety Trial For COX-2s, NSAIDs Urged By FDA

Executive Summary

FDA would like to see an "ALLHAT"-like study conducted with COX-2 inhibitors and non-selective NSAIDs to determine the relative gastrointestinal and cardiovascular safety of the two drug classes

You may also be interested in...



Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study

Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13

Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study

Pfizer's support for a massive study of Celebrex safety brings the drug maker together with researchers who have been urging the company to conduct additional trials; Pfizer approached Cleveland Clinic cardiovascular researchers about conducting the trial, which was announced Dec. 13

Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return

Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS045425

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel